




RealRate

PHARMACEUTICAL 2018

Dicerna Pharmaceuticals Inc
Rank 181 of 349



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai



PHARMACEUTICAL 2018

Dicerna Pharmaceuticals Inc Rank 181 of 349

The relative strengths and weaknesses of Dicerna Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Dicerna Pharmaceuticals Inc compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 274% points. The greatest weakness of Dicerna Pharmaceuticals Inc is the variable Net Income, reducing the Economic Capital Ratio by 111% points.

The company's Economic Capital Ratio, given in the ranking table, is -188%, being 89% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	118,558
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	16,646
Liabilities, Non-Current	0
Other Assets	814
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	3,000
Other Net Income	539
Property and Equipment	1,512
Research and Development	36,983
Revenues	2,277
Selling, General and Administrative Expense	25,881

Output Variable	Value in 1000 USD
Assets	120,884
Liabilities	19,646
Expenses	62,864
Stockholders Equity	101,238
Net Income	-60,048
Comprehensive Net Income	-60,048
Economic Capital Ratio	-188%

